Literature DB >> 9138285

Mighty mice: transgenic technology "knocks out" questions of matrix metalloproteinase function.

S D Shapiro1.   

Abstract

Matrix metalloproteinases (MMP) comprise a family of structurally related proteinases that are believed to play a critical role in many physiological and pathological processes. Transgenic technology offers the possibility of determining whether MMPs contribute directly to these processes. For example, gain of function and loss of function models have confirmed causative roles of MMPs in the development of pulmonary emphysema and unexpectedly uncovered an MMP-dependent mechanism of inflammatory cell recruitment. Limitations of these techniques and powerful applications on the horizon are also presented as we embark on an era where controlled experiments can be performed in complex mammalian models.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138285     DOI: 10.1016/s0945-053x(97)90027-5

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  9 in total

Review 1.  Recent advances in molecular biological techniques and their relevance to pulmonary research.

Authors:  B W Robinson; D J Erle; D A Jones; S Shapiro; W J Metzger; S M Albelda; W C Parks; A Boylan
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

Review 2.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 3.  Animal models of chronic obstructive pulmonary disease.

Authors:  P A Dawkins; R A Stockley
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

4.  Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis.

Authors:  A Jiang; K Lehti; X Wang; S J Weiss; J Keski-Oja; D Pei
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 5.  Chronic obstructive pulmonary disease * 3: Experimental animal models of pulmonary emphysema.

Authors:  R Mahadeva; S D Shapiro
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

6.  Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions.

Authors:  B Dubois; S Masure; U Hurtenbach; L Paemen; H Heremans; J van den Oord; R Sciot; T Meinhardt; G Hämmerling; G Opdenakker; B Arnold
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

7.  Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome.

Authors:  K L Andrews; T Betsuyaku; S Rogers; J M Shipley; R M Senior; J H Miner
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 8.  The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders.

Authors:  S Elliott; T Cawston
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 9.  [COPD: An early disease].

Authors:  V Margelidon-Cozzolino; K Chbini; N Freymond; G Devouassoux; A Belaaouaj; Y Pacheco
Journal:  Rev Pneumol Clin       Date:  2015-12-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.